comprehensive -WSS

comprehensive

author：fashion 2025-09-06 01:52:31 - browse：7842

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

explore

WSS

Data don't support strong claims for Covid

Eli Lilly’s Zepbound improved liver scarring in mid

STAT Virtual Event: JPM Recap, Live!

Merck to acquire Harpoon Therapeutics for $680 million

Hospital chaplains balance Covid safety with patients’ spiritual needs

A preacher's new calling: Diversifying neuroscience research

focus

comprehensive

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How CO2 helps viruses stay alive longer in the air

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Virtual Event: JPM Recap, Live!

After affirmative action ruling, medical educators look to 'holistic review'

Profiling embryos to choose those with higher IQs is almost a reality

hotspot

Gene therapy denied for Afghan refugee whose father aided U.S.

Life science postdocs should get big pay hike, NIH panel says

Stopping antidepressants leads to symptoms for 1 in 6 patients

Hospital chaplains balance Covid safety with patients’ spiritual needs

STAT wants to know your pick for a great summer read or listen

FDA approves Moderna’s RSV vaccine, its second licensed product

focus

entertainment

explore

focus